From 29 to 31 May, the American Society of Clinical Oncology (ASCO) will hold its annual scientific meeting. This is the largest, and one of the most important, oncology meetings in the calendar year.
For the first time, ASCO20 will be held virtually adapting its programme and sessions to the COVID-19 situation. The programme will still feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and speciality tracks. All presentations will be available on the ASCO20 website for a period of 180-days. Continue reading
Myeloma Patients Europe (MPE) held a webinar on personalised medicines in myeloma and AL amyloidosis given by Ellen Watters, Myeloma Information Nurse Specialist at Myeloma UK (MUK). Continue reading
Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020. Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on the impact of myeloma and AL amyloidosis in carers on Wednesday 20 May 2020 from 18:00 – 19:00 CET.
The webinar will be given by Ellen Watters, Myeloma Information Nurse Specialist at Myeloma UK (MUK), who will give a 40-minute presentation followed by a 20-minute Q&A session.
Myeloma Patients Europe (MPE) held a webinar on personalised medicines in myeloma and AL amyloidosis given by Dr Francesca Bonello, Università degli Studi di Torino, in Italy. Continue reading
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for daratumumab (Darzalex®) subcutaneous (SC) formulation for the treatment of adult patients with myeloma in frontline and relapsed/refractory settings. Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on personalised medicines in myeloma and AL amyloidosis on Wednesday 6 May 2020 from 18:00 – 19:00 CET. Continue reading
Myeloma Patients Europe (MPE) held a webinar Minimal Residual Disease (MRD) in myeloma and related diseases given by Paula van Hennik, Committee for Medicinal Products for Human Use (CHMP) member at the European Medicine Agency (EMA). Continue reading
The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus). Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on Minimal Residual Disease (MRD) in myeloma and related diseases on Monday 20 April 2020 from 18:00 – 19:00 CET. Continue reading